Vostok Pulsar · Biomedicine
Breakthrough biomedical technologies and medicines
Vostok Pulsar is the biomedical ray: breakthrough biomedical technologies and medicines, Scientific Teams and laboratory partnerships.
Programmes
Own programmes in active development
Ischaemic stroke
A recombinant IGF-1-LONG hybrid protein, proposed to protect the ischaemic penumbra and activate post-ischaemic neurogenesis through the IGF-1 receptor pathway. This is a research hypothesis at the planning stage, not a demonstrated effect.
Multiple sclerosis
Recombinant somatotropin and / or recombinant IGF-1, proposed for neuroprotection and symptom reduction in relapsing-remitting and progressive multiple sclerosis. In a mouse model of the disease, rhIGF-1 stimulated T-regulatory cell proliferation and suppressed the immune response (EMBO Molecular Medicine). This is a research hypothesis at the planning stage, not a demonstrated effect in patients.
Both are in active development: study design and partners are being prepared.
Target product profile
Competitive analysis shows what a medicine must offer to earn its place among existing treatments.
Investment case
Investors and pharmaceutical companies back candidates with a clear advantage over what already exists. Further detail on the profile is available in our closed data room.
Risk mitigation
Where current medicines are affordable, safe and effective, another drug with the same mechanism may not be worth developing.
Preclinical study design
Competitive analysis determines what to measure before clinical work, to show superiority or a clear difference.
- 2priority programmes
Ischaemic stroke and multiple sclerosis, at the development stage. Evidence, access to materials, intellectual property, delivery resources and funding are being assessed for each.
- 4opportunities under assessment
The next wave of evaluation. They have not started as programmes: Anti-Senescence Vaccine; Non-Opioid Analgesia — HNP-1/2/3 plasmid DNA; Polyvalent Influenza Vaccine; Universal Pneumonia Vaccine (S. pneumoniae chimeric).
- 5reserve concepts
Held in reserve for future assessment: Rotavirus Vaccine (FliC-VP6-VP8); Anti-Tuberculosis Vaccine (Ag85B / TB10.4 / FliC); HPV-14 Therapeutic Vaccine (plasmid DNA); Cartilage Regeneration Fusion Protein; Oncology Humanised mAbs (Syndecan-1 + Legumain).
These priority programmes are under development, and their prospects are being evaluated.
Open to Scientific Teams
We are open to Scientific Teams and laboratory partners. A Scientific Team may be a single researcher.